Serratus plain block versus paravertebral block versus serratus plain block and paravertebral block for postoperative pain following thoracoscopic surgery

Serratus plain block versus paravertebral block versus serratus plain block and paravertebral block for postoperative pain following thoracoscopic surgery - THORACOSCOPIC

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2019-002858-23-FR

Enrollment

156

Registered

2019-07-29

Start date

2019-11-20

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain following thoracoscopic surgery

Interventions

Trade Name: ROPIVACAINE KABI 2 mg/ml, solution injectable en ampoule Product Name: ROPIVACAÏNE Product Code: N01BB09 Pharmaceutical Form: Injection Pharmaceutical form of the placebo: Solution for inf

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patient over 18 years old - video-assisted thoracospic surgery with 3 trocars, Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 36

Exclusion criteria

Exclusion criteria: - Minor patient - Refusal of locoregional analgesia - Patient with a history of chronic pain under opioids or patients with impossible pain assessment - Substance addiction - Surgical procedure with thoracic nerve damage (especially pleural abrasion) - Thoracotomy surgical procedure, assisted video mini-thoracotomy - Contraindication to locoregional analgesia (allergy, skin condition)

Design outcomes

Primary

Measure	Time frame
Main Objective: to compare efficiency of serratus plain block versus paravertebral block versus serratus plain block and paravertebral block for postoperative pain following thoracoscopic surgery;Secondary Objective: are to compare between the 3 groups: • The visual analog scale: END at rest and postoperative cough at H1, H3, H6, D1, D2, D3, and at discharge from hospital. • Postoperative opioid consumption • Failure rate of locoregional analgesia evaluated in the operating room • Respiratory morbidity (duration of drainage, hospitalization and rate of pneumonitis) • Evaluation of postoperative chronic pain in control consultation at 6 months of intervention ;Primary end point(s): Pain visual analog scale (VAS) at cougthing evaluated at H0 following thoracoscopic surgery;Timepoint(s) of evaluation of this end point: day 1	—

Measure

Time frame

Main Objective: to compare efficiency of serratus plain block versus paravertebral block versus serratus plain block and paravertebral block for postoperative pain following thoracoscopic surgery;Secondary Objective: are to compare between the 3 groups: • The visual analog scale: END at rest and postoperative cough at H1, H3, H6, D1, D2, D3, and at discharge from hospital. • Postoperative opioid consumption • Failure rate of locoregional analgesia evaluated in the operating room • Respiratory morbidity (duration of drainage, hospitalization and rate of pneumonitis) • Evaluation of postoperative chronic pain in control consultation at 6 months of intervention ;Primary end point(s): Pain visual analog scale (VAS) at cougthing evaluated at H0 following thoracoscopic surgery;Timepoint(s) of evaluation of this end point: day 1

—

Secondary

Measure	Time frame
Secondary end point(s): Analog visual scale: END at rest and at postoperative cough at H1, H3, H6, D1, D2, D3, and at discharge from hospital, informed according to the usual computer protocol of the establishment by a qualified nurse state, in the recovery room and in the thoracic surgery department. • Use of opioid therapies during the period of hospitalization • Failure rate of locoregional analgesia assessed in SSPI • Duration of thoracic drainage. • Duration of hospitalization. • Respiratory morbidity - rate of pneumonitis. • Evaluation of postoperative chronic pain in control consultation at 6 months of intervention using the following secondary endpoints: Evaluation of the pain by NDS and DN4 + NeuPSIG (neuropathic pain) scale and evaluation of the consumption of antalgic therapies ;Timepoint(s) of evaluation of this end point: day 1, 2, 3 and at 6 months	—

Measure

Time frame

Secondary end point(s): Analog visual scale: END at rest and at postoperative cough at H1, H3, H6, D1, D2, D3, and at discharge from hospital, informed according to the usual computer protocol of the establishment by a qualified nurse state, in the recovery room and in the thoracic surgery department. • Use of opioid therapies during the period of hospitalization • Failure rate of locoregional analgesia assessed in SSPI • Duration of thoracic drainage. • Duration of hospitalization. • Respiratory morbidity - rate of pneumonitis. • Evaluation of postoperative chronic pain in control consultation at 6 months of intervention using the following secondary endpoints: Evaluation of the pain by NDS and DN4 + NeuPSIG (neuropathic pain) scale and evaluation of the consumption of antalgic therapies ;Timepoint(s) of evaluation of this end point: day 1, 2, 3 and at 6 months

—

Countries

France

Contacts

Public ContactProject Manager

CHU Amiens-Picardie

mattoug.salah@chu-amiens.fr333 2208 83 85

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026